Clinical Trial Update: CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of CD40 agonist APX005M (sotigalimab) with nivolumab in cancer including metastatic non-small cell lung cancer and melanoma has completed with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Melanoma
• Neoplasm of Lung
• Non-small Cell Lung Cancer

Drugs mentioned

• APX005M
• nivolumab (nivolumab)

Snippet

Sponsor: Apexigen America, Inc. | Conditions: Cancer, Non Small Cell Lung Cancer Metastatic | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-12-05